Healio (7/13, Oldt) reports that in a 418-patient, “double-blind, placebo-controlled, randomized” phase 3 study, “lisdexamfetamine dimesylate reduced risk for relapse in moderate to severe binge-eating disorder over six months.” The findings were published online July 12 in JAMA Psychiatry. Psychiatric News (7/12) also covered the study.

Related Links:

— “Lisdexamfetamine dimesylate lowers binge-eating disorder relapse risk,” Hudson JI, et al., Healio, July 13, 2017.

Rheumatology News (7/12, Dotinga) reports, “Most patients who were prescribed opioid” analgesics “did not go back for a refill right away, but nearly half of patients who stopped taking the drugs for at least six months ended up using them again over a three-year period,” researchers found after analyzing “medical and pharmacy data from 2009-2012 for 2.5 million people.” The findings were presented at the American Psychiatric Association’s annual meeting.

Related Links:

— “Nearly Half of Patients Who Stop Taking Opioids for 6 Months Resume Use Later,” Randy Dotinga, Rheumatology News, July 12, 2017.

Medscape (7/12, Brooks) reports, “The antidepressant fluoxetine (multiple brands) may help ease hypochondriasis, and adding cognitive-behavioral therapy (CBT) provides a small incremental benefit,” researchers found. The findings of the 195-patient study were published online June 29 in the American Journal of Psychiatry, a publication of the American Psychiatric Association.

Related Links:

— Medscape (requires login and subscription)

Reuters (7/12, Seaman) reports, “Pregnant women’s use of antidepressants does not increase their babies’ risk of intellectual disability,” researchers found. The findings were published online July 12 in JAMA Psychiatry.

HealthDay (7/12, Preidt) reports investigators arrived at that conclusion after tracking “data on more than 179,000 children born in Sweden in 2006 and 2007, including about 4,000 whose mothers took antidepressants during pregnancy.”

Healio (7/12, Oldt) reports that included in the study were children “exposed to selective serotonin reuptake inhibitor (SSRI) antidepressants, all other non-SSRI antidepressants, or other nonantidepressant psychotropic medications.”

Related Links:

— “Antidepressants in pregnancy not tied to intellectual disability in kids,” Andrew M. Seaman, Reuters>, July 12, 2017.

California Healthline (7/11, Korry) reports a class-action lawsuit filed in the District Court for the Northern District of California alleges that Blue Shield of California “wrongly restricted patients’ access to outpatient and residential mental health treatment” by developing “criteria that violate accepted professional standards and the terms of the health plan itself” along with Magellan Health Services of California.

Blue Shield said it disagrees “with the allegations in the lawsuit” and plans to “defend the case vigorously.” According to California Healthline, “The plaintiffs seek to change Blue Shield’s and Magellan’s policies to be consistent with the law, generally accepted professional standards and the terms of its own plans, according to the lawsuit.”

According to Dr. Anita Everett, president of the American Psychiatric Association, “A win in this case would mean that ‘medically necessary’ means just that, necessary as an objective medical matter not medically necessary only if not too expensive.”

Related Links:

— “Blue Shield Improperly Denied Mental Health, Drug Treatment Claims, Suit Alleges,” Elaine Korry, California Healthline, July 11, 2017.